How to Use K-M Survival Curves to Become a Smarter Investor

apropos of nothing, I was reading Adam Feuerstein's column this week (as is my wont) and came across a cut down version of an article I read years ago.

I think the article is not only relevant for investor analysis of clinical data, but also illustrative of the relative value of Opdivo (one of the examples he uses).

https://www.thestreet.com/story/139...ival-curves-to-become-a-smarter-investor.html

Anyway, as there isn't much going on in these threads right now, I thought some might find it interesting